Joseph Mikhael
Joseph Mikhael

Joseph Mikhael M.D.

Applied Cancer Research and Drug Discovery

Joseph Mikhael M.D.

Dr. Mikhael is a Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center.  He is also the Chief Medical Officer of the International Myeloma Foundation (IMF).  He also serves as a Councilor on the Executive of the American Society of Hematology.

He specializes clinically in plasma cell disorders, namely multiple myeloma, amyloidosis and Waldenstrom’s macroglobulinemia. Dr. Mikhael is currently the principal investigator of many clinical trials, primarily in relapsed multiple myeloma, and incorporating immunotherapies into the treatment algorithm of this incurable disease.  He has helped develop Isatuximab (a CD38 monoclononal antibody) from its infancy, soon to be in the clinic.  

His other clinical research interests also include pharmaco-economics, communication skills and media relations.  He has published over 100 peer reviewed articles in these fields. He lectures internationally on a regular basis. He is an active member of the International Myeloma Working Group, and serves on the editorial board of JCO.

Dr. Mikhael is also deeply involved in training future researchers, as he mentors junior hematologists nationwide.  He was recently the co-chair of the American Society of Hematology Clinical Research Training Institute (CRTI). This is a week-long intense course designed to train up and coming clinical researchers in blood diseases and cancer.

Dr. Mikhael will be working closely with Dr. Jonathon Keats and his lab at TGen. 

Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, Stewart AK, Bergsagel PL, Fonseca R. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012 May 10; 119: (19)4391-4. PMID:22331188   PMCID:3557400   DOI:10.1182/blood-2011-11-390930

Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ, Mayo Clinic. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013 Apr; 88: (4)360-76. PMID:23541011   DOI:10.1016/j.mayocp.2013.01.019  

Mikhael JR, Reeder CB, Libby EN, Costa LJ, Bergsagel PL, Buadi F, Mayo A, Nagi Reddy SK, Gano K, Dueck AC, Stewart AK. Phase IbII trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma. Br J Haematol. 2015 Apr; 169: (2)219-27. PMID:25683772   PMCID:4521972   DOI:10.1111/bjh.13296

Sung L, Rego E, Riva E, Elwood J, Basso J, Clayton CP, Mikhael J. Development and Evaluation of a Hematology-Oriented Clinical Research Training Program in Latin America. J Cancer Educ. 2016 Mar 15; PMID:26976436   DOI:10.1007/s13187-016-1015-4   

Mikhael J. Management of Carfilzomib-Associated Cardiac Adverse Events. Clin Lymphoma Myeloma Leuk. 2016 May; 16: (5)241-5. PMID:26907720   DOI:10.1016/j.clml.2016.01.008  

Lipe B, Vukas R, Mikhael J. The role of maintenance therapy in multiple myeloma. Blood Cancer J. 2016 Oct 21; 6: (10)e485. PMID:27768093   PMCID:5098261   DOI:10.1038/bcj.2016.89

Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. 2017 Sep 07; 130 (10):1198-1204 Epub 2017 July 06 PMID:28684537   PMCID:5606008   DOI:10.1182/blood-2017-05-782961

Mikhael JR. Maintenance Lenalidomide After Transplantation in Multiple Myeloma Prolongs Survival-In Most. J Clin Oncol. 2017 Oct 10; 35 (29):3269-3271 Epub 2017 Aug 23 PMID:28834440 doi:10.1200/JCO.2017.74.7014 

Costello C, Mikhael JR. Therapy sequencing strategies in multiple myeloma: who, what and why? Future Oncol 2018 Jan; 14 (2):95-99 Epub 2017 Dec 08

Marshall AL, Jenkins S, Mikhael J, Gitlin SD. Determinants of hematology-oncology trainees' postfellowship career pathways with a focus on nonmalignant hematology. Blood Adv. 2018 Feb 27; 2 (4):361-369  

Laubach JP, van de Donk N, Davies FE, Mikhael J. Practical Considerations for Antibodies in Myeloma. 2018

ASCO Educational Book pp. 667–674.

Back To Top